VANCOUVER, BRITISH COLUMBIA, November 2, 2020 - Pascal Biosciences, Inc. ("Pascal" or the"Company") (TSX VENTURE: PAS), a biotechnology company that specializes in cancer drug discovery and development, wishes to announce that it has re-priced the debt settlement agreements with certain…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 23, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19.…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 16, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has been invited to present at the International Cannabinoid Derived Pharmaceutical (ICDP) Summit. Today Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in…
Read MoreOur exciting partnership with SōRSE Technology has been featured on an article in Reuters. We invite you to read more here: https://www.reuters.com/article/us-pascal-cancer-sorse/canadas-pascal-biosciences-partners-with-sorse-to-test-cannabis-based-cancer-therapy-idUSKBN2651VC
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 14, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement (the “Agreement”) to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, August 4, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) is pleased to announce that its common shares were accepted for listing on the Frankfurt Stock Exchange (“FSE”) under the trading symbol…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, July 14, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the Company has discovered certain cannabinoids that block replication of SARS-CoV-2, the coronavirus that causes COVID-19. In a cell-based…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, July 9, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the appointment of Dr. H. Michael Shepard to its Board of Directors. Dr. Shepard was a 2019 recipient…
Read MoreNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA, May 27, 2020 – Pascal Biosciences Inc. (TSX.V: PAS) ("Pascal") entered into a non-binding term sheet with SōRSE Technology Corporation ("SōRSE")…
Read MoreNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V: PAS) ("Pascal") is pleased to announce that it has entered into a…
Read More